| | | | |
CUSIP No. 55083R104 | | 13G | | Page 6 of 8 Pages |
Item 1(a). | Name of Issuer: |
Lyell Immunopharma, Inc.
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
201 Haskins Way
South San Francisco, California
(a) – (c) Name of Persons Filing; Address; Citizenship
This statement on Schedule 13(G) is being filed jointly by the following persons, collectively, the “Reporting Persons”:
Address: c/o Trident Trust Company (B.V.I.) Limited, Trident Chambers, P.O. Box 146, Road Town, Tortola, British Virgin Islands
Citizenship: British Virgin Islands
| ii. | Orland Properties Limited |
Address: c/o Trident Trust Company (B.V.I.) Limited, Trident Chambers, P.O. Box 146, Road Town, Tortola, British Virgin Islands
Citizenship: British Virgin Islands
Address: c/o Trident Trust Company (Cayman) Limited, One Capital Place, P.O. Box 847, Grand Cayman, KY1-1103, Cayman Islands
Citizenship: Cayman Islands
| iv. | Gemini Investments, L.P. |
Address: c/o Trident Trust Company (Cayman) Limited, One Capital Place, P.O. Box 847, Grand Cayman, KY1-1103, Cayman Islands
Citizenship: Cayman Islands
Item 2(d). | Title of Class of Securities: |
Common Stock, $0.0001 par value (“Common Stock”)
55083R104